Chronic Venous Insufficiency (CVI) is a progressive vascular disorder of the lower extremities characterized by venous hypertension, retrograde blood flow (reflux), and impaired venous return. Driven by valvular incompetence and vein wall remodeling in the superficial, deep, or perforator venous systems, CVI ranges from cosmetic telangiectasias and symptomatic varicose veins to intractable edema, lipodermatosclerosis, and active venous stasis ulcerations.

Historically, definitive management of superficial truncal reflux required open surgical high ligation and saphenous vein stripping (HL/S) under general or spinal anesthesia. While effective, open surgery involved surgical incisions, prolonged recovery times, hematoma formation, and a high incidence of groin neovascularization leading to recurrence.

Over the past two decades, minimally invasive endovascular interventions have transformed the standard of care. Modern clinical management centers around Endovenous Thermal Ablation—principally Endovenous Laser Ablation (EVLA)—and Chemical Sclerotherapy (liquid and ultrasound-guided foam). Selecting the optimal modality requires aligning venous caliber, anatomical location, tortuosity, and clinical severity under the CEAP classification framework.

1. Pathophysiology and CEAP Clinical Staging

Lower-extremity venous return relies on competent one-way bicuspid valves, the foot/calf muscle pump, and physiological intra-abdominal pressure dynamics. Valvular dysfunction allows hydrostatic pooling, leading to persistent ambulatory venous hypertension.

This elevated pressure damages the microcirculation, activating endothelial cells and triggering leukocyte extravasation into the dermis. The subsequent release of transforming growth factor-beta (TGF-beta), matrix metalloproteinases (MMPs), and inflammatory cytokines causes progressive tissue fibrosis, hyperpigmentation, and ulceration.

The internationally standardized CEAP Classification (Clinical, Etiology, Anatomy, Pathophysiology) defines clinical severity:

• C0: No visible or palpable signs of venous disease.
• C1: Telangiectasias (spider veins < 1 mm) or reticular veins (1 to 3 mm).
• C2: True varicose veins (subcutaneous dilated, tortuous veins >= 3 mm).
• C3: Venous edema without chronic skin changes.
• C4a: Pigmentation (hemosiderin deposition) or venous eczema.
• C4b: Lipodermatosclerosis (dermal sclerosis and fat necrosis) or atrophie blanche.
• C5: Healed venous stasis ulceration.
• C6: Active, open venous stasis ulceration.

Duplex ultrasound remains the diagnostic cornerstone, with pathological reflux defined as retrograde flow lasting greater than 500 milliseconds (0.5 seconds) in the superficial and perforator veins, or greater than 1000 milliseconds (1.0 second) in the femoral and popliteal deep veins.

2. Endovenous Laser Ablation (EVLA): Thermal Obliteration

Endovenous Laser Ablation (EVLA) is the primary first-line therapeutic standard for straight, incompetent saphenous trunks, including the Great Saphenous Vein (GSV), Small Saphenous Vein (SSV), and Anterior Accessory Saphenous Vein (AASV).

• Mechanism of Action:

• Under direct ultrasound guidance, a percutaneous micro-puncture introduces a laser fiber into the target saphenous vein, positioned strictly 1.5 to 2.0 cm distal to the saphenofemoral junction (SFJ) or saphenopopliteal junction (SPJ) to protect the deep femoral and popliteal veins.
• Modern laser systems utilize longer wavelengths (e.g., 1470 nm radial-emitting fibers) that target water in the vessel wall rather than intravascular hemoglobin.
• The delivered thermal energy denatures collagen in the vein wall, causing transmural endothelial destruction, immediate luminal shrinkage, localized thrombosis, and permanent fibrotic occlusion within 6 to 12 months.

• Mandatory Tumescent Anesthesia:

• Prior to laser firing, a chilled, dilute anesthetic solution (buffered lidocaine, epinephrine, and sodium bicarbonate in normal saline) is injected into the perivenous saphenous space under continuous ultrasound guidance.
• Triple Function: Acts as a protective heat sink to prevent thermal injury to adjacent cutaneous sensory nerves and skin, compresses the vein lumen against the laser fiber for optimal energy transfer, and provides regional intraoperative analgesia.

• Clinical Performance: EVLA achieves long-term anatomical occlusion rates of 93% to 98% at 5 years, outperforming older surgical stripping techniques with significantly lower post-procedural pain, zero general anesthesia requirements, and immediate same-day ambulation.

3. Sclerotherapy: Chemical Endothelial Destruction

Sclerotherapy involves the targeted intravascular injection of a chemical sclerosing agent to destroy the endothelial lining, provoking vasospasm, endofibrosis, and permanent vessel closure.

• Sclerosing Agents and Classes:

• Detergent Sclerosants: Polidocanol (POL) and Sodium Tetradecyl Sulfate (STS). These agents disrupt cell surface tension and extract cell-membrane lipids, causing rapid endothelial denudation. Polidocanol also possesses mild intrinsic local anesthetic properties, making injections virtually painless.
• Osmotic Agents: Hypertonic saline (23.4%) dehydrates endothelial cells via acute osmotic gradients; used less frequently due to intense localized cramping and severe skin necrosis risk if extravasated.

• Liquid vs. Foam Sclerotherapy (Tessari Technique):

• Liquid Sclerotherapy: Reserved primarily for small-caliber C1 spider veins and reticular vessels (< 3 mm). In large veins, blood rapidly dilutes liquid sclerosant, washing it away before therapeutic endothelial contact occurs.
• Ultrasound-Guided Foam Sclerotherapy (UGFS): Created by mixing sclerosant liquid with gas (air or physiological carbon dioxide/oxygen mixture) through a three-way stopcock in a 1:4 liquid-to-gas ratio (Tessari method).
• Advantage of Foam: Microfoam physically displaces blood from the lumen rather than diluting inside it, ensuring direct, concentrated chemical contact with the entire circumference of the vein wall while using significantly smaller total drug volumes.

• Primary Clinical Niches: UGFS is the definitive treatment of choice for tortuous, winding tributary veins, recurrent varices following prior surgery, incompetent perforating veins, and venous malformations that cannot accommodate a rigid, straight laser fiber.

4. Structural Comparison: EVLA vs. Sclerotherapy

• Primary Biological Mechanism:

• Endovenous Laser Ablation (EVLA): High-temperature thermal denaturation of collagen in the vein wall, causing immediate shrinkage and fibrotic occlusion.
• Sclerotherapy (UGFS / Liquid): Chemical detergent destruction of endothelial cell membranes, causing endofibrosis and luminal thrombosis.

• Optimal Anatomical Target:

• Endovenous Laser Ablation (EVLA): Long, straight, incompetent truncal veins (Great Saphenous Vein, Small Saphenous Vein, AASV).
• Sclerotherapy (UGFS / Liquid): Tortuous superficial tributaries, recurrent postoperative varicosities, perforators, and C1 telangiectasias.

• 5-Year Primary Occlusion Rate:

• Endovenous Laser Ablation (EVLA): High (93% to 98%).
• Sclerotherapy (UGFS / Liquid): Moderate (70% to 85% for large truncal veins; requires more repeat sessions).

• Anesthesia Requirements:

• Endovenous Laser Ablation (EVLA): Ultrasound-guided perivenous tumescent local anesthesia along the entire treated vein length.
• Sclerotherapy (UGFS / Liquid): None; performed via direct needle puncture without tumescence.

• Anatomical Limitations:

• Endovenous Laser Ablation (EVLA): Cannot navigate severe venous tortuosity, sharp angulations, or acute aneurysmal dilatations.
• Sclerotherapy (UGFS / Liquid): Highly adaptable; liquid and foam flow freely through irregular, branching, and winding vessels.

• Major Complication Profile:

• Endovenous Laser Ablation (EVLA): Endovenous Heat-Induced Thrombosis (EHIT), thermal sensory nerve injury (saphenous/sural nerve paresthesia), skin burns.
• Sclerotherapy (UGFS / Liquid): Cutaneous hyperpigmentation (hemosiderin staining), superficial thrombophlebitis, transient visual scotomas/migraines (due to microbubble transit), skin necrosis if extravasated.

5. Endovenous Heat-Induced Thrombosis (EHIT) Classification and Management

Following thermal ablation (EVLA), post-procedure duplex ultrasound (performed between 48 hours and 7 days) is mandatory to evaluate for Endovenous Heat-Induced Thrombosis (EHIT)—the propagation of induced thrombus from the ablated saphenous trunk across the junction into the deep venous system:

• EHIT Class 1: Thrombus extends up to the saphenofemoral junction (SFJ) but does not enter the common femoral vein (CFV).

• Management: Conservative observation; no anticoagulation required; repeat ultrasound in 7 to 14 days.

• EHIT Class 2: Thrombus extends into the CFV, compromising less than 50% of the luminal diameter.

• Management: Weekly ultrasound surveillance or short-course prophylactic-to-therapeutic anticoagulation (e.g., DOAC or LMWH for 2 to 4 weeks) based on individual bleeding vs. extension risk.

• EHIT Class 3: Thrombus extends into the CFV, compromising greater than 50% of the luminal diameter.

• Management: Full therapeutic anticoagulation for 2 to 3 months, treating the condition as an acute deep vein thrombosis.

• EHIT Class 4: Complete, occlusive thrombosis of the Common Femoral Vein.

• Management: Full therapeutic anticoagulation for 3 to 6 months matching standard proximal DVT protocols.

6. Strategic Clinical Algorithm for Chronic Venous Disease

When evaluating a patient presenting with symptomatic lower-extremity chronic venous disease, execute a structured diagnostic and therapeutic sequence:

• Step 1: Clinical and Duplex Ultrasound Mapping: Perform bilateral standing duplex ultrasound to evaluate deep vein patency, map the saphenous junctions, measure trunk diameters, and quantify reflux durations in the GSV, SSV, and perforators.
• Step 2: Correct Underlying Truncal Reflux First: If saphenofemoral or saphenopopliteal junction incompetence is identified with truncal reflux > 500 ms in a straight vessel, perform first-line EVLA (or Radiofrequency Ablation). Never treat tributary varices with sclerotherapy in isolation without addressing upstream saphenous junction reflux, as high hydrostatic pressure guarantees rapid recurrence.
• Step 3: Manage Concomitant or Residual Branch Varicosities:

• In the same session or 4 to 6 weeks post-EVLA, treat tortuous, bulging tributary varices using Ultrasound-Guided Foam Sclerotherapy (UGFS) or Ambulatory Microphlebectomy (stab avulsion).

• Step 4: Treat Incompetent Perforators in Advanced C5/C6 Ulcer Disease: If an active venous ulcer (CEAP C6) fails to heal, identify incompetent sub-ulcer perforating veins and ablate them via targeted UGFS or laser fiber access.
• Step 5: Post-Procedural Compression & Early Ambulation: Apply graduated compression stockings (20 to 30 mmHg) immediately post-procedure for 3 to 7 days, and instruct the patient to walk for 20 to 30 minutes immediately after discharge to activate the deep calf pump and minimize deep vein thrombosis risk.
• Step 6: Refine Spider and Reticular Telangiectasias (CEAP C1): Following successful truncal and tributary closure, perform aesthetic Liquid Sclerotherapy (with 0.25% to 0.5% Polidocanol) for remaining spider and reticular veins.

10 Frequently Asked Questions (FAQs)

EVLA is performed under local tumescent anesthesia in an outpatient setting without surgical incisions. It provides equal or superior 5-year closure rates (>95%), involves significantly less post-operative pain and bruising, carries a lower risk of wound infections, and allows patients to resume normal daily activities immediately.

Ultrasound-guided foam sclerotherapy (UGFS) can close large varicose veins, but when used as monotherapy on large, straight saphenous trunks with high junctional reflux, its long-term recanalization rate is higher than EVLA. It is best utilized as an adjunct for tortuous branch varices, recurrent veins, or in patients unfit for thermal procedures.

Tumescent anesthesia serves three mandatory purposes: it numbs the perivascular tissue, compresses the vein wall tightly against the laser fiber for efficient energy absorption, and acts as a protective thermal heat sink to prevent heat from damaging the skin or adjacent sensory nerves.

Liquid sclerosant is diluted and washed away by circulating blood in vessels larger than 2 to 3 mm. Sclerosing foam (created by agitating sclerosant with gas in a 1:4 ratio) displaces intravascular blood, ensuring sustained, direct contact between the chemical agent and the endothelium using lower drug dosages.

Post-sclerotherapy hyperpigmentation occurs when red blood cells become trapped inside the thrombosed, treated vein lumen. The extravasated red blood cells break down, releasing hemosiderin iron deposits into the dermis. It can be minimized by evacuating trapped micro-thrombi with a fine needle 2 to 4 weeks post-procedure.

EHIT is a condition where the heat-induced thrombus created inside the saphenous vein extends into the lumen of the deep common femoral or popliteal vein. It is detected during post-procedure duplex ultrasound (within 48 to 72 hours) and graded from Class 1 (at the junction) to Class 4 (occlusive DVT) to guide observation vs. anticoagulation.

If a patient has an undiagnosed Patent Foramen Ovale (PFO) or cardiac right-to-left shunt, injected gas microbubbles can bypass pulmonary filtration and enter the cerebral circulation, triggering transient cortical spreading depression (manifesting as temporary visual scotomas or migraine auras).

If high-pressure reflux originating from an incompetent saphenofemoral junction or saphenous trunk is left uncorrected, the elevated hydrostatic column will transmit downstream pressure directly into the superficial reticular and spider networks, causing immediate treatment failure and rapid recurrence of spider veins.

Modern thermal ablation favors water-specific wavelengths (such as 1470 nm) delivered via jacketed radial-emitting fibers over older hemoglobin-specific 810/980 nm bare-tip lasers. 1470 nm lasers require lower total linear energy density (LEED), dramatically reducing post-operative ecchymosis, pain, and vein wall perforations.

Ablating superficial truncal and perforator reflux eliminates ambulatory venous hypertension at the ulcer bed. When combined with multi-layer compression therapy, minimally invasive ablation results in ulcer healing rates of 80% to 95% within 12 to 24 weeks, while significantly reducing long-term ulcer recurrence rates compared to compression alone.